EATG » HIV treatment

HIV treatment

Transmitted drug resistance now less likely to harm HIV treatment options, US study finds

The rising prevalence of transmitted antiretroviral drug resistance in the United States is unlikely to affect the success of first-line treatment in the future and is largely unconnected with recent…

ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine

London, 14 June 2018 - ViiV Healthcare today announced positive headline results from its phase III GEMINI study programme. The studies (GEMINI-1 and GEMINI-2) are designed to evaluate the safety…

ART simplification does not affect systemic inflammation in virologically suppressed HIV

For virologically suppressed patients infected with HIV, switching to a dual antiretroviral maintenance therapy of atazanavir/ritonavir plus lamivudine does not affect plasma markers of systemic inflammation, according to results published…

HIV i-Base: HIV Treatment Bulletin, 8 June 2018

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. In this issue of HTB: DTG, PK reports and more... The bulletin can be accessed here.

Weekly injections of PRO 140 in combination with optimized ART shows HIV-1 viral suppression

June 9, 2018 – Atlanta, GA – Results from a pivotal trial of PRO 140, a new HIV therapy, show that PRO 140 is an effective, long-acting therapeutic in combination…

Closer monitoring recommended for older patients treated with dolutegravir for HIV

The maximum concentration of the integrase inhibitor dolutegravir (DTG) was significantly higher in people living with HIV who are more than 60 years old compared with younger individuals, according to…

Cumulative ritonavir-boosted darunavir use may be associated with increased CVD risk

In patients infected with HIV, the cumulative use for ritonavir-boosted darunavir was associated with a progressively increasing risk for cardiovascular disease, according to research published in The Lancet HIV. Data…

FDA says Prezcobix should not be given to pregnant women

Darunavir/cobicistat — marketed as Prezcobix (Janssen) in the United States — should not be given to pregnant women with HIV because of substantially lower exposures of the two medications during…

Hepatitis B or raised liver enzymes predict liver toxicity when TB prevention drug is combined with HIV treatment

The risk of liver toxicity in people with HIV taking antiretroviral therapy and isoniazid preventive therapy for tuberculosis is strongly associated with either hepatitis B co-infection or pre-existing liver enzyme…

Drug to treat alcohol addiction also helps with suppression of HIV

A medication commonly prescribed to treat alcohol use disorder also appears to help maintain or improve suppression of HIV among individuals at risk for a lapse in HIV treatment, Yale…

1 2 3 56